Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Long-Term Deferred Tax (2020 - 2025)

China Pharma Holdings (CPHI) has disclosed Long-Term Deferred Tax for 7 consecutive years, with $22.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax changed N/A year-over-year to $22.7 million, compared with a TTM value of $22.7 million through Sep 2025, changed N/A, and an annual FY2024 reading of $21.7 million, changed N/A over the prior year.
  • Long-Term Deferred Tax was $22.7 million for Q3 2025 at China Pharma Holdings, up from $22.1 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $24.0 million in Q4 2021 and bottomed at $21.7 million in Q4 2024.
  • Average Long-Term Deferred Tax over 3 years is $22.5 million, with a median of $22.1 million recorded in 2025.
  • Peak annual rise in Long-Term Deferred Tax hit 13.32% in 2021, while the deepest fall reached 13.32% in 2021.
  • Year by year, Long-Term Deferred Tax stood at $24.0 million in 2021, then decreased by 9.52% to $21.7 million in 2024, then rose by 4.61% to $22.7 million in 2025.
  • Business Quant data shows Long-Term Deferred Tax for CPHI at $22.7 million in Q3 2025, $22.1 million in Q2 2025, and $21.9 million in Q1 2025.